Pharma医生组织与Aliant AI合作,为Teverelix试验建立一个AI平台,目的是在2026年提高效率。 Medicus Pharma partners with Reliant AI to build an AI platform for its Teverelix trial, aiming to boost efficiency in 2026.

Medvicus Pharma有限公司与Reliant AI Inc.公司签署了一份不具约束力的意向书,以开发一个AI驱动的临床数据分析平台,旨在提高其Teverelix方案的试验效率,Teverelix方案是下一代GNRH对急性尿液保留和心血管风险高的前列腺癌的对抗者。 Medicus Pharma Ltd. has signed a non-binding letter of intent with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at improving trial efficiency for its Teverelix program, a next-generation GnRH antagonist for acute urinary retention and high cardiovascular risk prostate cancer. 该平台预计将在2026年的一项研究中启动,它将利用基因人工智能,通过整合公共、商业和专利数据支持选址、病人分层和入学预测。 The platform, expected to launch in a 2026 study, will use generative AI to support site selection, patient stratification, and enrollment forecasting by integrating public, commercial, and proprietary data. 为期一年的里程碑式参与承诺最高为200 000美元,可以扩大到2028年的后期审判。 The one-year, milestone-based engagement has a maximum commitment of $200,000 and could expand to a 2028 late-stage trial. 最后条款将在具有约束力的协定中加以界定。 Final terms will be defined in binding agreements.